Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.69) by 14.49 percent. This is a 18.06 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $6.87 million which beat the analyst consensus estimate of $2.81 million by 144.31 percent. This is a 120.24 percent increase over sales of $3.12 million the same period last year.